Pfizer Recalls Bicillin L-A Due to Contamination, Threatening Syphilis Treatment Amid Rising Congenital Cases
Key Insights
Pfizer issued a voluntary recall of 12 lots of Bicillin L-A (penicillin G benzathine) after discovering floating particles during visual inspection, with no adverse events reported to date.
The recall threatens progress against congenital syphilis (search), which has increased tenfold from 335 cases in 2012 to over 3,800 cases in 2023, as Bicillin L-A is the only approved treatment for syphilis (search) during pregnancy.
Pfizer expects supply shortages and will implement rationing measures, requiring providers to fill out medical request forms for per-patient allocation while prioritizing pregnant patients.
Pfizer has issued a voluntary recall of 12 lots of Bicillin L-A (penicillin G benzathine injectable solution) after discovering floating particles during visual inspection, potentially disrupting critical treatment efforts against a surging congenital syphilis (search) epidemic in the United States. The pharmaceutical giant has warned healthcare providers to expect supply shortages of the long-acting penicillin injection, which serves as the only approved treatment for syphilis (search) during pregnancy.
The recall, announced July 10, affects both 1,200,000 units/2 mL and 2,400,000 units/4 mL formulations distributed across multiple lots with expiration dates ranging from 2026 to 2027. Pfizer has not received any reports of adverse events related to the recalled products, but the company identified the contamination source as defective stoppers supplied by an external vendor.
"We have identified the root cause to be associated with stoppers supplied from an external vendor and are implementing the appropriate corrective and preventative actions," Pfizer stated, emphasizing its commitment to patient safety while working to resolve the manufacturing issue.
Critical Impact on Congenital Syphilis Crisis
The timing of this recall poses significant public health concerns as the United States grapples with a dramatic surge in congenital syphilis (search) cases. According to CDC (search) data, congenital syphilis rates have increased tenfold over the past decade, rising from 335 cases in 2012 to more than 3,800 cases in 2023.
"We're in the midst of a congenital syphilis (search) crisis, and we've been calling for an emergency declaration for congenital syphilis for years," said Dr. Jeffrey Klausner, professor of clinical population and public health sciences at the University of Southern California's Keck School of Medicine. "This threatens to make that even worse."
Benzathine penicillin G represents the cornerstone of syphilis (search) treatment during pregnancy, as untreated syphilis can cause miscarriages, stillbirths, and fatal complications in infants. The infection can also lead to vision and hearing problems in babies, along with deformities of bones and teeth. A single injection of Bicillin L-A, when administered early in pregnancy, can prevent transmission to newborns.
Supply Management and Rationing Measures
Pfizer has announced it will implement rationing measures for available Bicillin L-A supplies until stock fully recovers. Healthcare providers will need to complete medical request forms, with the company distributing supplies on a per-patient basis. The company plans to provide supply updates no later than mid-August.
This shortage follows a previous supply disruption in 2023, during which Pfizer ceased pediatric dose production to prioritize adult formulations for pregnant patients. The company had expected to resume pediatric dose deliveries in October, though the current recall may affect this timeline.
The FDA has authorized imports of two equivalent products to help address supply constraints: Extencilline from France and Lentocilin (search) from Portugal, distributed through Mark Cuban's Cost Plus Drugs (search). However, these imported alternatives present logistical challenges for healthcare systems.
"In a health system, it's very hard to use imported products," explained Erin Fox, associate chief pharmacy officer at the University of Utah Health. The imported medications feature different bar coding systems not recognized by most hospital networks and may require different mixing and dilution protocols, creating potential confusion for healthcare providers.
Public Health Response and Testing Strategies
Several states have implemented aggressive testing and treatment protocols to combat rising congenital syphilis (search) rates, relying heavily on immediate Bicillin L-A administration. States including New Mexico and Minnesota have adopted strategies to test all pregnant women for syphilis (search) at multiple pregnancy stages and in emergency departments or urgent care settings.
These programs encourage providers to administer long-acting penicillin shots during the same visit as initial positive test results, without waiting for confirmatory testing. This approach has shown promising results, with a CDC (search) official noting recent data indicating a slowing of congenital syphilis (search) rates.
"With the latest release of data, we saw a slowing of rates, which was really exciting," said a CDC (search) official familiar with the data. "That progress is the result of hard work bringing awareness to controlling syphilis (search) and congenital syphilis (search)."
Manufacturing Vulnerabilities and Regulatory Response
The recall highlights the vulnerability of sterile injectable products to quality control issues and supply disruptions. As the sole US supplier of Bicillin, Pfizer's manufacturing problems create immediate nationwide shortages with limited alternative sources.
Particles in injectable solutions pose significant health risks, potentially causing inflammation, tissue damage, and life-threatening complications such as embolism, according to health officials. The Guam Department of Public Health and Social Services has coordinated with ExpressMed Pharmacy (search) to remove affected products from local shelves.
The National Coalition of STD Directors is gathering information from members to assess the recall's impact. During a recent committee meeting, participants reported returning substantial quantities of Bicillin doses to Pfizer, with one state returning approximately 800 vials.
"We had a small reprieve for about, maybe a year, in terms of steady supply. And now this is just a complete kick in the teeth and really threatens our ability to prevent and control syphilis (search)," Klausner said.
Funding and Resource Challenges
The recall compounds existing challenges in syphilis (search) control efforts, including recent federal funding cuts and staffing reductions. CDC (search) personnel working on syphilis control programs were affected by government layoffs, though approximately 200 positions were reinstated in June.
"I am concerned though that now, with a cut in funds to national and local STD programs, that we will start to see a drop in testing for syphilis (search)," the CDC (search) official noted. "Cuts to Medicaid and Medicare, as well as other programs, will be devastating for syphilis control."
The CDC (search) has recommended preserving available Bicillin L-A supplies specifically for treating pregnant patients given the dynamic nature of the supply situation and the critical importance of preventing congenital syphilis (search) transmission.